Marcy K. Vallone

Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome

Susan D. Demo, Christopher J. Kirk, Monette Aujay et al. · Cancer Research · 2007 · 668 citations · Full text

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

Owen A. O’Connor, A. Keith Stewart, Marcy K. Vallone et al. · Clinical Cancer Research · 2009 · 298 citations · Full text

Phase 1 Single Agent Antitumor Activity of Twice Weekly Consecutive Day Dosing of the Proteasome Inhibitor Carfilzomib (PR-171) in Hematologic Malignancies.

Melissa Alsina, Suzanne Trudel, Marcy K. Vallone et al. · Blood · 2007 · 52 citations

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

David S. Siegel, Thomas G. Martin, Michael Wang et al. · Blood · 2010 · 39 citations

Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer

Johanna C. Bendell, Thomas J. Ervin, David Gallinson et al. · Clinical Colorectal Cancer · 2013 · 33 citations

Study Design, Medicine, Treatment Rationale +9